Allergen immunotherapy as add-on to biologic agents

Area of Science:

• Allergy and Immunology
• Pharmacology
• Clinical Trials

Background:

• Allergen-specific immunotherapy (AIT) is a cornerstone treatment for allergic diseases.
• Biologic agents, such as omalizumab (OMA), are increasingly explored as adjuncts to AIT.
• Adverse events during AIT escalation phases necessitate exploring supportive therapies.

Purpose of the Study:

• To review current evidence on omalizumab (OMA) as an add-on therapy to allergen-specific immunotherapy (AIT).
• To assess the efficacy and safety of combining OMA with AIT for various allergic conditions.

Main Methods:

• Systematic review of available clinical trials and literature.
• Analysis of studies investigating omalizumab in conjunction with AIT.
• Evaluation of reported outcomes, including adverse events and treatment efficacy.

Main Results:

• Omalizumab (OMA) shows potential as an add-on to AIT for respiratory allergies and food desensitization.
• OMA may be particularly beneficial during the escalation phase of AIT to manage adverse events.
• Evidence for OMA in hymenoptera venom allergy is limited to case reports, lacking structured clinical trials.

Conclusions:

• Combining OMA with AIT presents promising results for specific allergic conditions.
• Larger randomized, double-blind, placebo-controlled trials are essential.
• Future research should focus on patient selection, optimal dosing, treatment duration, and pharmacoeconomic evaluations for OMA-AIT combinations.